Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons on 2-4 February 2022
05 February 2022 - 2:16AM
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members,
executives and associated persons on 2-4 February 2022
Bagsværd, Denmark, 4
February 2022 —
This company announcement discloses the data of the transaction(s)
made in Novo Nordisk shares by the company’s board members,
executives and their associated persons in accordance with Article
19 of Regulation No. 596/2014 on market abuse.
Members of Executive Management have participated in a long-term
incentive programme consisting of a one-year performance period
(2018) and a three-year vesting period (2019-2021). The shares
allocated have on 2 February 2022 been transferred to current and
former executives as specified below. No dividend has been paid to
the executives during the one-year performance period or the
three-year vesting period. For further information please see Novo
Nordisk’s Remuneration Report 2021.
The company’s board members, executives and their associated
persons have given Novo Nordisk power of attorney on their behalf
to publish trading in Novo Nordisk shares by the company’s board
members, executives and their associated persons.
Please find below a statement of such trading in shares issued
by Novo Nordisk.
|
1 |
Details of the person discharging managerial
responsibilities/person closely associated |
|
a) |
Name of the Board member/Executive/Associated Person |
Maha Kutay |
|
2 |
Reason for the notification |
|
a) |
Position/status |
Closely related to Kasim Kutay, member of the Board of
Directors |
|
b) |
Initial notification/Amendment |
Initial notification |
|
3 |
Details of the issuer |
|
a) |
Name |
Novo Nordisk A/S |
|
b) |
LEI |
549300DAQ1CVT6CXN342 |
|
4 |
Details of the transaction(s) |
|
a) |
Description of the financial instrument,type of instrument, |
Shares |
|
|
Identification code |
Novo Nordisk B DK0060534915 |
|
b) |
Nature of the transaction |
Purchase of shares |
|
c) |
Price(s) and volume(s) |
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
DKK 694.00 |
255 shares |
|
|
|
|
|
|
|
|
|
|
|
|
d) |
Aggregated information
|
255 sharesDKK 694.00 |
|
e) |
Date of the transaction |
2022-02-02 |
|
f) |
Place of the transaction |
Nasdaq Copenhagen |
|
1 |
Details of the person discharging managerial
responsibilities/person closely associated |
|
a) |
Name of the Board member/Executive/Associated Person |
Lars Fruergaard Jørgensen |
|
2 |
Reason for the notification |
|
a) |
Position/status |
President and CEO |
|
b) |
Initial notification/Amendment |
Initial notification |
|
3 |
Details of the issuer |
|
a) |
Name |
Novo Nordisk A/S |
|
b) |
LEI |
549300DAQ1CVT6CXN342 |
|
4 |
Details of the transaction(s) |
|
a) |
Description of the financial instrument,type of instrument, |
Shares |
|
|
Identification code |
Novo Nordisk B DK0060534915 |
|
b) |
Nature of the transaction |
Other transaction (transfer of shares inaccordance with long-term
incentiveprogramme) |
|
c) |
Price(s) and volume(s) |
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
DKK 0.00 |
76,619 shares |
|
|
|
|
|
|
|
|
|
|
|
|
d) |
Aggregated information
|
76,619 sharesDKK 0.00 |
|
e) |
Date of the transaction |
2022-02-03 |
|
f) |
Place of the transaction |
Outside a trading venue |
|
1 |
Details of the person discharging managerial
responsibilities/person closely associated |
|
a) |
Name of the Board member/Executive/Associated Person |
Lars Fruergaard Jørgensen |
|
2 |
Reason for the notification |
|
a) |
Position/status |
President and CEO |
|
b) |
Initial notification/Amendment |
Initial notification |
|
3 |
Details of the issuer |
|
a) |
Name |
Novo Nordisk A/S |
|
b) |
LEI |
549300DAQ1CVT6CXN342 |
|
4 |
Details of the transaction(s) |
|
a) |
Description of the financial instrument,type of instrument, |
Shares |
|
|
Identification code |
Novo Nordisk B DK0060534915 |
|
b) |
Nature of the transaction |
Sale of shares |
|
c) |
Price(s) and volume(s) |
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
DKK 695.91 |
40,000 shares |
|
|
|
|
|
|
|
|
|
|
|
|
d) |
Aggregated information
|
40,000 sharesDKK 695.91 |
|
e) |
Date of the transaction |
2022-02-02 |
|
f) |
Place of the transaction |
Nasdaq Copenhagen |
|
1 |
Details of the person discharging managerial
responsibilities/person closely associated |
|
a) |
Name of the Board member/Executive/Associated Person |
Maziar Mike Doustdar |
|
2 |
Reason for the notification |
|
a) |
Position/status |
Executive vice president, International Operations |
|
b) |
Initial notification/Amendment |
Initial notification |
|
3 |
Details of the issuer |
|
a) |
Name |
Novo Nordisk A/S |
|
b) |
LEI |
549300DAQ1CVT6CXN342 |
|
4 |
Details of the transaction(s) |
|
a) |
Description of the financial instrument,type of instrument, |
Shares |
|
|
Identification code |
Novo Nordisk B DK0060534915 |
|
b) |
Nature of the transaction |
Other transaction (transfer of shares inaccordance with long-term
incentiveprogramme) |
|
c) |
Price(s) and volume(s) |
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
DKK 0.00 |
23,947 shares |
|
|
|
|
|
|
|
|
|
|
|
|
d) |
Aggregated information
|
23,947 sharesDKK 0.00 |
|
e) |
Date of the transaction |
2022-02-03 |
|
f) |
Place of the transaction |
Outside a trading venue |
|
1 |
Details of the person discharging managerial
responsibilities/person closely associated |
|
a) |
Name of the Board member/Executive/Associated Person |
Karsten Munk Knudsen |
|
2 |
Reason for the notification |
|
a) |
Position/status |
Executive vice president, Chief Financial Officer |
|
b) |
Initial notification/Amendment |
Initial notification |
|
3 |
Details of the issuer |
|
a) |
Name |
Novo Nordisk A/S |
|
b) |
LEI |
549300DAQ1CVT6CXN342 |
|
4 |
Details of the transaction(s) |
|
a) |
Description of the financial instrument,type of instrument, |
Shares |
|
|
Identification code |
Novo Nordisk B DK0060534915 |
|
b) |
Nature of the transaction |
Other transaction (transfer of shares inaccordance with long-term
incentiveprogramme) |
|
c) |
Price(s) and volume(s) |
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
DKK 0.00 |
21,551 shares |
|
|
|
|
|
|
|
|
|
|
|
|
d) |
Aggregated information
|
21,551 sharesDKK 0.00 |
|
e) |
Date of the transaction |
2022-02-03 |
|
f) |
Place of the transaction |
Outside a trading venue |
|
1 |
Details of the person discharging managerial
responsibilities/person closely associated |
|
a) |
Name of the Board member/Executive/Associated Person |
Karsten Munk Knudsen |
|
2 |
Reason for the notification |
|
a) |
Position/status |
Executive vice president, Chief Financial Officer |
|
b) |
Initial notification/Amendment |
Initial notification |
|
3 |
Details of the issuer |
|
a) |
Name |
Novo Nordisk A/S |
|
b) |
LEI |
549300DAQ1CVT6CXN342 |
|
4 |
Details of the transaction(s) |
|
a) |
Description of the financial instrument,type of instrument, |
Shares |
|
|
Identification code |
Novo Nordisk B DK0060534915 |
|
b) |
Nature of the transaction |
Sale of shares |
|
c) |
Price(s) and volume(s) |
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
DKK 674.40 |
10,000 shares |
|
|
|
|
|
|
|
|
|
|
|
|
d) |
Aggregated information
|
10,000 sharesDKK 647.40 |
|
e) |
Date of the transaction |
2022-02-04 |
|
f) |
Place of the transaction |
Outside a trading venue |
|
1 |
Details of the person discharging managerial
responsibilities/person closely associated |
|
a) |
Name of the Board member/Executive/Associated Person |
Doug Langa |
|
2 |
Reason for the notification |
|
a) |
Position/status |
Executive vice president, North America Operations |
|
b) |
Initial notification/Amendment |
Initial notification |
|
3 |
Details of the issuer |
|
a) |
Name |
Novo Nordisk A/S |
|
b) |
LEI |
549300DAQ1CVT6CXN342 |
|
4 |
Details of the transaction(s) |
|
a) |
Description of the financial instrument,type of instrument, |
Shares |
|
|
Identification code |
Novo Nordisk B DK0060534915 |
|
b) |
Nature of the transaction |
Other transaction (transfer of shares inaccordance with long-term
incentiveprogramme) |
|
c) |
Price(s) and volume(s) |
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
DKK 0.00 |
23,947 shares |
|
|
|
|
|
|
|
|
|
|
|
|
d) |
Aggregated information
|
23,947 sharesDKK 0.00 |
|
e) |
Date of the transaction |
2022-02-03 |
|
f) |
Place of the transaction |
Outside a trading venue |
|
1 |
Details of the person discharging managerial
responsibilities/person closely associated |
|
a) |
Name of the Board member/Executive/Associated Person |
Doug Langa |
|
2 |
Reason for the notification |
|
a) |
Position/status |
Executive vice president, North America Operations |
|
b) |
Initial notification/Amendment |
Initial notification |
|
3 |
Details of the issuer |
|
a) |
Name |
Novo Nordisk A/S |
|
b) |
LEI |
549300DAQ1CVT6CXN342 |
|
4 |
Details of the transaction(s) |
|
a) |
Description of the financial instrument,type of instrument, |
Shares |
|
|
Identification code |
Novo Nordisk B DK0060534915 |
|
b) |
Nature of the transaction |
Sale of shares |
|
c) |
Price(s) and volume(s) |
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
DKK 697.55 |
12,113 shares |
|
|
|
|
|
|
|
|
|
|
|
|
d) |
Aggregated information
|
12,113 sharesDKK 697.55 |
|
e) |
Date of the transaction |
2022-02-03 |
|
f) |
Place of the transaction |
Nasdaq Copenhagen |
|
1 |
Details of the person discharging managerial
responsibilities/person closely associated |
|
a) |
Name of the Board member/Executive/Associated Person |
Camilla Sylvest |
|
2 |
Reason for the notification |
|
a) |
Position/status |
Executive vice president, Commercial Strategy & Corporate
Affairs |
|
b) |
Initial notification/Amendment |
Initial notification |
|
3 |
Details of the issuer |
|
a) |
Name |
Novo Nordisk A/S |
|
b) |
LEI |
549300DAQ1CVT6CXN342 |
|
4 |
Details of the transaction(s) |
|
a) |
Description of the financial instrument,type of instrument, |
Shares |
|
|
Identification code |
Novo Nordisk B DK0060534915 |
|
b) |
Nature of the transaction |
Other transaction (transfer of shares inaccordance with long-term
incentiveprogramme) |
|
c) |
Price(s) and volume(s) |
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
DKK 0.00 |
21,551 shares |
|
|
|
|
|
|
|
|
|
|
|
|
d) |
Aggregated information
|
21,551 sharesDKK 0.00 |
|
e) |
Date of the transaction |
2022-02-03 |
|
f) |
Place of the transaction |
Outside a trading venue |
|
1 |
Details of the person discharging managerial
responsibilities/person closely associated |
|
a) |
Name of the Board member/Executive/Associated Person |
Camilla Sylvest |
|
2 |
Reason for the notification |
|
a) |
Position/status |
Executive vice president, Commercial Strategy & Corporate
Affairs |
|
b) |
Initial notification/Amendment |
Initial notification |
|
3 |
Details of the issuer |
|
a) |
Name |
Novo Nordisk A/S |
|
b) |
LEI |
549300DAQ1CVT6CXN342 |
|
4 |
Details of the transaction(s) |
|
a) |
Description of the financial instrument,type of instrument, |
Shares |
|
|
Identification code |
Novo Nordisk B DK0060534915 |
|
b) |
Nature of the transaction |
Sale of shares |
|
c) |
Price(s) and volume(s) |
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
DKK 682.79 |
10,000 shares |
|
|
|
|
|
|
|
|
|
|
|
|
d) |
Aggregated information
|
10,000 sharesDKK 682.79 |
|
e) |
Date of the transaction |
2022-02-03 |
|
f) |
Place of the transaction |
Nasdaq Copenhagen |
|
1 |
Details of the person discharging managerial
responsibilities/person closely associated |
|
a) |
Name of the Board member/Executive/Associated Person |
Henrik Wulff |
|
2 |
Reason for the notification |
|
a) |
Position/status |
Executive vice president, Product Supply, Quality & IT |
|
b) |
Initial notification/Amendment |
Initial notification |
|
3 |
Details of the issuer |
|
a) |
Name |
Novo Nordisk A/S |
|
b) |
LEI |
549300DAQ1CVT6CXN342 |
|
4 |
Details of the transaction(s) |
|
a) |
Description of the financial instrument,type of instrument, |
Shares |
|
|
Identification code |
Novo Nordisk B DK0060534915 |
|
b) |
Nature of the transaction |
Other transaction (transfer of shares inaccordance with long-term
incentiveprogramme) |
|
c) |
Price(s) and volume(s) |
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
DKK 0.00 |
23,947 shares |
|
|
|
|
|
|
|
|
|
|
|
|
d) |
Aggregated information
|
23,947 sharesDKK 0.00 |
|
e) |
Date of the transaction |
2022-02-03 |
|
f) |
Place of the transaction |
Outside a trading venue |
Definitions and background information:
PublicationPublication shall take place no
later than three working days after the trading by board members,
executives or their associated persons. Publication is only
required when the total amount of transactions of a specific board
member/executive or his/her associated persons in any one calendar
year has reached EUR 20,000 (calculated individually).
Who are board members, executives and associated
persons?Board members and executives are members of the
Board of Directors and Executive Management, respectively, of Novo
Nordisk A/S. Associated persons are defined as the following
persons associated to a board member/executive: 1) spouse or
cohabitant, 2) children under the age of 18 years, 3) Other
relatives defined as brothers, sisters, parents, grandparents,
children, grandchildren, cousins etc. who have shared the same
household with a board member or executive for a period of at least
one year on the date of the given transaction and 4) any legal
persons, trust, or partnership, the managerial responsibilities of
which are discharged by a board member/executive or by a person
referred to in items 1)-3) above, or which is directly or
indirectly controlled by such a person, or which is set up for the
benefit of such a person, or the economic interests of which are
substantially equivalent to those of such a person.
What is trading/transaction?Trading is any kind
of transaction, including shares and share related securities
purchased or otherwise acquired, sold or otherwise disposed, gifts,
mortgages, heritage and grants, allotments and exercise of
options.
What is financial instrument and ID code?
Financial instrument includes shares listed on the Nasdaq
Copenhagen and ADRs listed on New York Stock Exchange, except for
ADRs held in 401(k) retirement plan by US-based employees. The ID
code is the code (ISIN DK0060534915) of the Novo Nordisk share on
the Nasdaq Copenhagen or the code (NVO) on New York Stock
Exchange.
What is date and place of transaction?Date of
transaction is the actual transaction date. The place of
transaction is the actual place of transaction, i.e. Nasdaq
Copenhagen or New York Stock Exchange.
What is the volume and price of transaction and
aggregated information?The volume of transaction is the
number of shares (of DKK 0.20 nominal value) or other financial
instruments traded. In case of a single transaction the price is
the price of that single transaction. In case of multiple
transactions, when the transactions relate to the same financial
instrument, are of the same nature, are executed on the same day
and are executed on the same place, the volume must be aggregated.
The price of the aggregated transactions is the weighted average
price.
The exchange rate of the Danish Central Bank (Nationalbanken) on
the date of transaction is used for calculating the transaction
value in DKK in case of ADRs listed on New York Stock Exchange.
Novo Nordisk is a leading global healthcare company, founded in
1923 and headquartered in Denmark. Our purpose is to drive change
to defeat diabetes and other serious chronic diseases such as
obesity and rare blood and endocrine disorders. We do so by
pioneering scientific breakthroughs, expanding access to our
medicines and working to prevent and ultimately cure disease. Novo
Nordisk employs about 47,800 people in 80 countries and markets its
products in around 170 countries. Novo Nordisk's B shares are
listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the
New York Stock Exchange (NVO). For more information, visit
novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.
Further information
| Media: |
|
|
| Mette Kruse
Danielsen |
+45 4442
3883 |
mkd@novonordisk.com |
| Michael Bachner
(US) |
+1 609 664
7308 |
mzyb@novonordisk.com |
| |
|
|
| Investors: |
|
|
| Daniel Muusmann
Bohsen |
+45 3075
2175 |
dabo@novonordisk.com |
| Ann Søndermølle
Rendbæk |
+45 3075
2253 |
arnd@novonordisk.com |
| David Heiberg
Landsted |
+45 3077
6915 |
dhel@novonordisk.com |
| Jacob Martin
Wiborg Rode |
+45 3075
5956 |
jrde@novonordisk.com |
| Mark Joseph
Root |
+45 3079
4211 |
mjhr@novonordisk.com |
Company announcement No 08 / 2022
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Jan 2025 to Feb 2025
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Feb 2024 to Feb 2025
